N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: Synthesis and biological evaluation. 2021

Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
School of Pharmacy, Lanzhou University, Lanzhou, 730000, China.

Glioblastoma is one of the most lethal brain tumors. The crucial chemotherapy is mainly alkylating agents with modest clinical success. Given this desperate need and inspired by the encouraging results of a phase II trial via concomitant Topo I inhibitor plus COX-2 inhibitor, we designed a series of N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents based on structure modification on 1,5-naphthyridine derivatives (Topo I inhibitors). Notably, the target compounds I-1 (33.61 ± 1.15 μM) and I-8 (45.01 ± 2.37 μM) were confirmed to inhibit COX-2, while a previous reported compound (1,5-naphthyridine derivative) resulted nearly inactive towards COX-2 (IC50 > 150 μM). Besides, I-1 and I-8 exhibited higher anti-proliferation, anti-migration, anti-invasion effects than the parent compound 1,5-naphthyridine derivative, suggesting the success of modification based on the parent. Moreover, I-1 obviously repressed tumor growth in the C6 glioma orthotopic model (TGI = 66.7%) and U87MG xenograft model (TGI = 69.4%). Besides, I-1 downregulated PGE2, VEGF, MMP-9, and STAT3 activation, upregulated E-cadherin in the orthotopic model. More importantly, I-1 showed higher safety than temozolomide and different mechanism from temozolomide in the C6 glioma orthotopic model. All the evidence demonstrated that N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents could be promising for the glioma management.

UI MeSH Term Description Entries
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001549 Benzamides BENZOIC ACID amides.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
January 2014, Combinatorial chemistry & high throughput screening,
Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
January 2020, Medicinal chemistry (Shariqah (United Arab Emirates)),
Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
December 2018, Bioorganic chemistry,
Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
October 2012, Journal of enzyme inhibition and medicinal chemistry,
Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
January 2014, Medicinal chemistry (Shariqah (United Arab Emirates)),
Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
April 2012, European journal of medicinal chemistry,
Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
July 2017, Bioorganic & medicinal chemistry letters,
Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
January 2022, Brazilian journal of biology = Revista brasleira de biologia,
Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
April 2018, Computational biology and chemistry,
Junfang Li, and Xiaoling Hu, and Tian Luo, and Yingmei Lu, and Yiyue Feng, and Honghua Zhang, and Dan Liu, and Xiaohong Fan, and Yuqing Wang, and Liming Jiang, and Yuying Wang, and Xiangyong Hao, and Tao Shi, and Zhen Wang
March 2014, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!